Video
Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer
Author(s):
Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.
Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.
Over the last few years, CDK4/6 inhibitors have impacted clinical practice due to their ability to double progression-free survival. Thus far, of all of the 3 CDK4/6 inhibitors that are approved by the FDA, the trials had PFS as their primary endpoint. However, an overall survival analysis (OS) was integrated into these studies. MONALEESA-7 is the first of these trials to have reached that landmark and show a survival benefit, Tripathy explains.
The updated data of the phase III trial showed that treatment with ribociclib (Kisqali) and endocrine therapy demonstrated a statistically significant improvement in OS compared with placebo/endocrine therapy in this patient population, Tripathy concludes.
